Gerald J Dal Pan

List of Publications by Year
in descending order

18	387	840585 11	839398 18
papers	citations	h-index	g-index

18	18	18	352
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of FDA safetyâ€•related drug label changes in 2010. Pharmacoepidemiology and Drug Safety, 2013, 22, 302-305.	0.9	91
2	Ongoing Challenges in Pharmacovigilance. Drug Safety, 2014, 37, 1-8.	1.4	41
3	Postâ€market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiology and Drug Safety, 2012, 21, 1134-1136.	0.9	33
4	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Safety, 2015, 38, 565-575.	1.4	31
5	Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. Clinical Pharmacology and Therapeutics, 2018, 104, 390-400.	2.3	31
6	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiology and Drug Safety, 2017, 26, 712-721.	0.9	27
7	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health and Surveillance, 2018, 4, e1.	1.2	21
8	â€œArtificial Intelligenceâ€•for Pharmacovigilance: Ready for Prime Time?. Drug Safety, 2022, 45, 429-438.	1.4	21
9	Communicating the Risks of Medicines. Medical Care, 2012, 50, 463-465.	1.1	16
10	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug Safety, 2020, 43, 329-338.	1.4	15
11	Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance. Drug Safety, 2019, 42, 649-655.	1.4	14
12	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety, 2019, 42, 1287-1295.	1.4	13
13	An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. Drug Safety, 2020, 43, 457-465.	1.4	13
14	Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. Journal of Law, Medicine and Ethics, 2019, 47, 430-441.	0.4	9
15	Changes in emergency department visits for zolpidemâ€attributed adverse drug reactions after FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety, 2020, 29, 352-356.	0.9	4
16	The Impact of Litigation-Associated Reports on Signal Identification in the US FDAâ€™s Adverse Event Reporting System. Drug Safety, 2019, 42, 1199-1201.	1.4	3
17	The Use of Realâ€World Data to Assess the Impact of Safetyâ€Related Regulatory Interventions. Clinical Pharmacology and Therapeutics, 2022, 111, 98-107.	2.3	3
18	Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. Pharmacoepidemiology and Drug Safety, 2021, 30, 1551-1559.	0.9	1